NRx Pharmaceuticals completes MOU with distribution partners for HTX-100

NRx Pharmaceuticals and its wholly owned subsidiary HOPE Therapeutics announced completion of a Memorandum of Understanding with Conversio Health, a national 503a pharmacy, and an ongoing partnership with Nephron Pharmaceuticals, a manufacturer of Ketamine and 503b pharmacy to provide IV Ketamine to patients and clinics across the country, subject to board approval. The company has further entered into a business relationship with an organization that currently serves the business needs of more than 100 ketamine clinics nationwide. The Company has been given a target delivery date prior to the end of this month for initial stock of ketamine for sale to licensed end users. Sales are planned to commence once technical and logistical elements are finalized. “We are pleased to be working with two outstanding organizations in Conversio Health and Nephron Pharmaceuticals to provide this important medication to a market in need of a consistent supply of high-quality, FDA- and DEA- compliant IV ketamine,” said Matthew Duffy Chief Business Officer of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics.